Science & Research
Viromed Medical AG Completes Study on Cold Plasma Application in the Lung, Shows Promise for Treating Ventilator-Associated Pneumonia
Viromed Medical AG announces successful completion of a multi-year study on cold atmospheric plasma in the lung, demonstrating potential as a non-pharmacological treatment for severe infectious lung diseases, with first successful patient applications already achieved.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Lucid-MS and Commercial Product unbuzzd™
Quantum BioPharma's lead drug Lucid-MS targets nerve damage in multiple sclerosis, with a Phase 2 trial upcoming, while its alcohol metabolism product unbuzzd™ generates royalty revenue.
Regentis Biomaterials Advances Simplified Cartilage Repair Platform Toward Key Milestones
Regentis Biomaterials is moving its cell-free hydrogel implant GelrinC toward U.S. market entry, targeting a $3 billion knee cartilage repair market with a simplified procedure that could replace traditional microfracture and cell-based therapies.
Heart Disease Risk Rising Among U.S. Women, New Report Warns
A new American Heart Association statement projects that by 2050, 6 in 10 U.S. women will have cardiovascular disease, driven by rising obesity, diabetes, and high blood pressure, but highlights prevention strategies to reverse the trend.
Regentis Biomaterials Targets $3 Billion U.S. Knee Cartilage Repair Market with Novel Off-the-Shelf Solution
Regentis Biomaterials' GelrinC platform offers a potential first-in-class, ready-to-use knee cartilage repair treatment with superior pain relief and faster recovery, advancing through U.S. Phase III trials.
Inhalable Viral Vector Shows Promise in Treating Advanced Lung Cancer
A new inhalable viral-based vector could enhance anti-cancer immune responses and restore sensitivity to immune checkpoint inhibitors in patients with advanced lung cancer.
Lantern Pharma Reports Phase 2 HARMONIC Trial Data Showing LP-300 Benefit in EGFR-Mutant Lung Cancer
Lantern Pharma announced updated Phase 2 data for LP-300 in EGFR L858R-mutant non-small cell lung cancer, showing improved progression-free survival and a clean safety profile, with an FDA-cleared protocol amendment extending dosing to eight cycles.
Nevada Organic Phosphate Reports Encouraging Preliminary Results from Murdock Mountain Drill Hole
Nevada Organic Phosphate Inc. reported promising preliminary observations from a drill hole at its Murdock Mountain Property, intersecting a 15.3-meter section of the Meade Peak unit, with further drilling underway.
iOrganBio Adds Leading Neurobiologist Dr. Zhiping Pang to Scientific Advisory Board
iOrganBio appoints Dr. Zhiping Pang, a top expert in human neuron biology and neuropsychiatric disorders, to its Scientific Advisory Board, strengthening its position in AI-enabled human cell manufacturing for research and therapeutics.
Regentis Biomaterials Nears Key Milestones for Simplified Cartilage Repair Implant
Regentis Biomaterials advances GelrinC, a single-step hydrogel implant for knee cartilage repair, targeting a $3 billion U.S. market with CE Mark approval and a Phase III trial over 50% enrolled.
Oncotelic Therapeutics Advances Drug-Delivery Platform as Industry Focuses on Enhancing Existing Therapies
Oncotelic Therapeutics is progressing its Sapu003 program and Deciparticle platform to improve oncology drug delivery and bioavailability, aligning with industry trends favoring advanced delivery technologies over new compound development.
Scandium Canada partners with University of Waterloo MSAM Lab to advance additive manufacturing of aluminum-scandium alloys
Scandium Canada Ltd. signed a non-disclosure agreement with the University of Waterloo's Multi-Scale Additive Manufacturing Laboratory to research and commercialize aluminum-scandium alloys for 3D printing, aiming to reduce costs and expand market opportunities.
Six Peptide Compounds Dominate 2026 Laboratory Research, Review Finds
A new review from cheat codes identifies BPC-157, TB-500, CJC-1295, Ipamorelin, Selank, and Epithalon as the most studied research peptides in preclinical literature, highlighting their potential implications for future therapeutic development.
Regentis Biomaterials Advances Cell-Free Knee Cartilage Implant, Targeting Major Market Gap
Regentis Biomaterials is advancing GelrinC, a ready-to-use hydrogel implant for knee cartilage repair, addressing a U.S. market of approximately 470,000 annual cases lacking an approved off-the-shelf regenerative solution.
Regentis Biomaterials Advances Toward Key Milestones for Simplified Cartilage Repair Platform
Regentis Biomaterials Ltd. is progressing its GelrinC hydrogel implant toward European commercialization and U.S. FDA submission, targeting a $3 billion market for knee cartilage repair with a cell-free, single-step procedure.
Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access
Optimi Health Corp. highlights Australia's updated TGA framework for psilocybin and MDMA, which broadens therapy teams and treatment settings, potentially accelerating adoption of psychedelic-assisted therapy.
Tonix Pharmaceuticals Highlights Persistent Opioid Use in Fibromyalgia Patients Despite Guidelines
A Tonix Pharmaceuticals study reveals that 40% of fibromyalgia patients still receive opioid prescriptions, underscoring a gap between clinical practice and evidence-based recommendations and highlighting the need for non-opioid treatments like TONMYA.
No Agenda Show Skeptical of NASA's $20 Billion Lunar Economy Pitch
In episode 1872, hosts Adam Curry and John C. Dvorak deconstruct media coverage of NASA's proposed $20 billion moon base and 'lunar economy,' questioning its feasibility amid pressing Earth-bound issues.
Regentis Biomaterials Targets $3 Billion Knee Cartilage Repair Market with Off-the-Shelf GelrinC Platform
Regentis Biomaterials’ GelrinC platform shows promise as a first-in-class, off-the-shelf solution for knee cartilage repair, with clinical data indicating approximately 100% greater pain improvement versus microfracture and a clear path to U.S. market entry.
Quantum BioPharma Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma is progressing its clinical-stage multiple sclerosis program targeting demyelination, a novel strategy distinct from immune-modulating therapies, while maintaining a diversified portfolio including consumer wellness products and sufficient capital through 2028.
Sino Biological's Cell-Free Protein Synthesis Powers AI-Driven Protein Design Study Published in Nature Communications
Sino Biological's XPressMAX Cell-Free Protein Synthesis Kit enabled rapid experimental validation of AI-designed proteins in a study by Tencent AI for Life Sciences Lab, achieving over 100-fold activity improvements and thermostable enzymes.
Regentis Biomaterials Targets Major Gap in Knee Cartilage Repair with Off-the-Shelf Implant
Regentis Biomaterials Ltd. is advancing GelrinC, a cell-free hydrogel implant for knee cartilage repair, which could address a significant unmet need in the U.S. market where no off-the-shelf regenerative solution currently exists.
Andina Copper Confirms New Porphyry Copper System at Piuquenes North
Andina Copper Corp. has intersected a multiphase porphyry copper system at the Piuquenes North target, confirming a third mineralized porphyry system on the property and expanding the exploration potential in San Juan, Argentina.
Western Star Resources Confirms Multiple Tungsten Zones at Rowland Property in Nevada
Western Star Resources has completed Phase 1 exploration at its Rowland Tungsten Property in Nevada, confirming four zones of extensive historical tungsten workings, indicating the property is more prospective than previously thought.
Tonix Pharmaceuticals Presents Data on High Economic Burden of Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals presented real-world data at ISPOR 2026 showing that over 93% of fibromyalgia patients have comorbidities and incur substantial healthcare costs, highlighting the unmet need for effective treatments as the company prepares to launch TONMYA.
NanoViricides Proposes NV-387 for Bundibugyo Ebola Outbreak Amid Lack of Approved Treatments
NanoViricides highlights its broad-spectrum antiviral NV-387 as a potential treatment for the Bundibugyo Ebola outbreak in Africa, where no approved vaccines or therapies exist, leveraging its host-targeted mechanism and oral formulation for easier deployment.
Regentis Biomaterials Targets Knee Cartilage Repair Market with Off-the-Shelf Hydrogel Implant
Regentis Biomaterials advances GelrinC, a cell-free hydrogel implant for knee cartilage repair, as clinical trials progress and a new manufacturing process scales production.
MAX Power Mining to Present Lawson Natural Hydrogen Discovery at Japan Industry Events, Highlighting Growing Global Interest
MAX Power Mining CEO will showcase the Lawson Natural Hydrogen Discovery at two major Japanese industry events, signaling international interest in Canada's first confirmed subsurface natural hydrogen system.
Sexual Difficulties Common in Young Cancer Survivors, Study Finds
A new doctoral study from Karolinska Institutet reveals that young adults often experience sexual problems after cancer treatment, with severity varying by cancer type and treatment intensity.
Better Heart Health Before Pandemic Linked to Lower Risk of Severe COVID-19
Adults with higher heart health scores before the pandemic were nearly half as likely to be hospitalized or die from COVID-19, according to new research in the Journal of the American Heart Association.